Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball, Alexa B, Arielle G Bensimon, Annie Guérin, Andrew P Yu, Eric Q Wu, Martin M Okun, Yanjun Bao, Shiraz R Gupta, and Parvez M Mulani. 2011. “Efficacy and Safety of Adalimumab Among Patients With Moderate to Severe Psoriasis With Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.”. American Journal of Clinical Dermatology 12 (1): 51-62.